[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  d_stock [@d_stock07734](/creator/twitter/d_stock07734) on x XXX followers Created: 2025-07-23 19:09:22 UTC Such a fabulous detect work! Thanks @andrewcaravello Merck first completed the building XX for Pneumococcal Conjugate Vaccine and the project even won an excellence reward. The interesting part is that right after the completion of the building 63, Merck added building 63A with the manufacturing capacity over 70m pre-filled syringes. Is there a huge market demand for PCV? Take a look at the hectic working hours Merck adopted to complete 63A. Why did Merck try to finish the construction in such a hurry? The 63A project was initiated in December 2020 to provide a facility to house a multi-product syringe filling line that will deliver the safe, compliant, and reliable annual production of XX million pre-filled syringes. The project will increase doses of vaccines by adding drug product capacity at the Merck PA manufacturing site. The vaccine produced helps protect individuals against diseases and related cancers. To achieve this goal, the project heavily utilized Lean tools, and developed a model termed ‘EPCM Integrator’ that would ensure meeting the project’s schedule and cost target. Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma Sponsor Mayo Clinic Study Start (Actual): 2017-11-15 Primary Completion (Actual): 2020-06-14 Principal Investigator:Matthew S. Block, M.D., Ph.D.,Mayo Clinic Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma Study Start (Actual): 2010-11 Primary Completion (Actual): 2015-11-24 Study Chair:Yi Lin, M.D.,Mayo Clinic Dendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Phase I/II Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation and Anti-PD-1 Antibody (Pembrolizumab) for Patients With Non-Hodgkin Lymphoma Study Start (Actual): 2017-08-15 Primary Completion (Actual): 2022-01-25 Principal Investigator:Yi Lin, MD, PhD,Mayo Clinic  XXX engagements  **Related Topics** [syringes](/topic/syringes) [$nwbo](/topic/$nwbo) [$mrk](/topic/$mrk) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/d_stock07734/status/1948098128332345582)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
d_stock @d_stock07734 on x XXX followers
Created: 2025-07-23 19:09:22 UTC
Such a fabulous detect work! Thanks @andrewcaravello
Merck first completed the building XX for Pneumococcal Conjugate Vaccine and the project even won an excellence reward. The interesting part is that right after the completion of the building 63, Merck added building 63A with the manufacturing capacity over 70m pre-filled syringes. Is there a huge market demand for PCV? Take a look at the hectic working hours Merck adopted to complete 63A. Why did Merck try to finish the construction in such a hurry?
The 63A project was initiated in December 2020 to provide a facility to house a multi-product syringe filling line that will deliver the safe, compliant, and reliable annual production of XX million pre-filled syringes. The project will increase doses of vaccines by adding drug product capacity at the Merck PA manufacturing site. The vaccine produced helps protect individuals against diseases and related cancers. To achieve this goal, the project heavily utilized Lean tools, and developed a model termed ‘EPCM Integrator’ that would ensure meeting the project’s schedule and cost target.
Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
Sponsor Mayo Clinic Study Start (Actual): 2017-11-15 Primary Completion (Actual): 2020-06-14 Principal Investigator:Matthew S. Block, M.D., Ph.D.,Mayo Clinic
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
Study Start (Actual): 2010-11 Primary Completion (Actual): 2015-11-24 Study Chair:Yi Lin, M.D.,Mayo Clinic
Dendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Phase I/II Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation and Anti-PD-1 Antibody (Pembrolizumab) for Patients With Non-Hodgkin Lymphoma
Study Start (Actual): 2017-08-15 Primary Completion (Actual): 2022-01-25 Principal Investigator:Yi Lin, MD, PhD,Mayo Clinic
XXX engagements
Related Topics syringes $nwbo $mrk stocks healthcare